Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers made small fortunes thanks to their work in this space.However, Pfizer and Moderna's revenue and earnings dropped significantly once the pandemic receded, as did their share prices; both stocks are down substantially in the past three years. If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option? Let's find out.Pfizer has made important moves in the past few years that could pay off down the line. It earned approval for several medicines and vaccines, including Litfulo, a therapy for alopecia areata, and Abrysvo, a respiratory syncytial virus (RSV) vaccine. The drugmaker also made several acquisitions, the most important of which was that of Seagen, a cancer specialist, for $43 billion. Pfizer's pipeline now features many oncology products, and others in various therapeutic areas.Continue reading
In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers made small fortunes thanks to their work in this space.
However, Pfizer and Moderna's revenue and earnings dropped significantly once the pandemic receded, as did their share prices; both stocks are down substantially in the past three years. If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option? Let's find out.
Pfizer has made important moves in the past few years that could pay off down the line. It earned approval for several medicines and vaccines, including Litfulo, a therapy for alopecia areata, and Abrysvo, a respiratory syncytial virus (RSV) vaccine. The drugmaker also made several acquisitions, the most important of which was that of Seagen, a cancer specialist, for $43 billion. Pfizer's pipeline now features many oncology products, and others in various therapeutic areas.
